EVA is registered trademark of Stern Stewart.
Economic value added or economic profit is the difference between revenues and costs,where costs include not only expenses, but also cost of capital.
Paying user area
Try for free
Vertex Pharmaceuticals Inc. pages available for free this week:
- Income Statement
- Common-Size Balance Sheet: Assets
- Common Stock Valuation Ratios
- Enterprise Value to FCFF (EV/FCFF)
- Capital Asset Pricing Model (CAPM)
- Selected Financial Data since 2005
- Return on Equity (ROE) since 2005
- Return on Assets (ROA) since 2005
- Debt to Equity since 2005
- Price to Sales (P/S) since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Vertex Pharmaceuticals Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Economic Profit
12 months ended: | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
---|---|---|---|---|---|---|
Net operating profit after taxes (NOPAT)1 | ||||||
Cost of capital2 | ||||||
Invested capital3 | ||||||
Economic profit4 |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 NOPAT. See details »
2 Cost of capital. See details »
3 Invested capital. See details »
4 2024 Calculation
Economic profit = NOPAT – Cost of capital × Invested capital
= – × =
- Net Operating Profit After Taxes (NOPAT)
- The NOPAT exhibited significant fluctuations over the observed period. Beginning at approximately 3.02 billion US dollars in 2020, it declined sharply to around 2.24 billion in 2021. This was followed by a recovery to nearly 2.99 billion in 2022. However, the figure again decreased to approximately 2.64 billion in 2023. A dramatic reversal occurred in 2024 with NOPAT turning negative, reaching about -1.27 billion US dollars, indicating operational challenges or substantial losses in that year.
- Cost of Capital
- The cost of capital remained relatively stable across the years. It started at 8.73% in 2020, maintained almost identical levels through to 2024, hovering between 8.72% and 8.76%. This consistency suggests that the company’s perceived risk and capital structure components were stable during this period.
- Invested Capital
- Invested capital displayed an increasing trend from 2020 through 2023, starting at approximately 8.14 billion US dollars and growing to about 13.24 billion US dollars. In 2024, invested capital experienced a steep decline to roughly 9.05 billion US dollars. This reduction might reflect asset disposals, write-downs, or divestitures undertaken during that year.
- Economic Profit
- Economic profit followed a pattern similar to NOPAT but showed more variability. Beginning at around 2.31 billion US dollars in 2020, it declined to approximately 1.42 billion in 2021, then rose to about 1.83 billion in 2022. A decline ensued in 2023 to approximately 1.48 billion, followed by a steep drop to negative 2.06 billion US dollars in 2024. The transition to negative economic profit in 2024 signifies that the company's returns failed to cover its cost of capital, marking a deterioration in value creation.
- Overall Observations
- The company's financial performance exhibited volatility with a notable downturn in 2024. Despite stable cost of capital, the sharp decline in invested capital and transition to negative NOPAT and economic profit suggests operational or strategic difficulties. The negative economic profit in 2024 indicates value destruction, highlighting the need for potential reassessment of investments and operational efficiency going forward.
Net Operating Profit after Taxes (NOPAT)
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 Elimination of deferred tax expense. See details »
2 Addition of increase (decrease) in equity equivalents to net income (loss).
3 2024 Calculation
Interest expense on capitalized operating leases = Operating lease liability × Discount rate
= × =
4 2024 Calculation
Tax benefit of interest expense = Adjusted interest expense × Statutory income tax rate
= × 21.00% =
5 Addition of after taxes interest expense to net income (loss).
6 2024 Calculation
Tax expense (benefit) of investment income = Investment income, before tax × Statutory income tax rate
= × 21.00% =
7 Elimination of after taxes investment income.
- Net Income (Loss)
-
The net income displayed an initial fluctuation with a decline from approximately 2.71 billion US dollars in 2020 to 2.34 billion US dollars in 2021. This was followed by a notable recovery reaching about 3.32 billion US dollars in 2022 and a further increase to approximately 3.62 billion US dollars in 2023. However, there was a significant reversal in 2024, with net income turning negative, resulting in a loss of approximately 536 million US dollars. This indicates a considerable downturn or an extraordinary expense impacting profitability in 2024.
- Net Operating Profit After Taxes (NOPAT)
-
The NOPAT value exhibited a similar pattern to net income but with some differences in magnitude and trend continuation. It started at around 3.02 billion US dollars in 2020 but dropped substantially to about 2.24 billion US dollars in 2021. There was a recovery in 2022 to nearly 3 billion US dollars; however, unlike net income that increased in 2023, NOPAT decreased to approximately 2.64 billion US dollars. In 2024, the NOPAT also turned negative, with a loss of about 1.27 billion US dollars, representing an even more pronounced operational challenge than indicated by net income alone.
- Summary of Trends and Insights
-
Both profitability measures show volatility over the five-year period with initial declines, strong recoveries, and significant downturns at the end of the period. The negative figures in 2024 for both net income and NOPAT highlight a substantial deterioration in performance. The larger negative NOPAT compared to net income in 2024 suggests a more severe erosion of operational efficiency or higher operating costs that may not be fully captured in net income calculations. These trends warrant further investigation into underlying causes such as market conditions, cost management, one-time charges, or other financial events impacting the company's profitability in the latest period.
Cash Operating Taxes
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
- Provision for income taxes
- The provision for income taxes displayed fluctuations over the observed period. It decreased from 405,151 thousand US dollars in 2020 to 388,300 thousand US dollars in 2021, indicating a slight reduction. However, in 2022, there was a significant increase to 910,400 thousand US dollars. Following this peak, the provision decreased somewhat in 2023 to 760,200 thousand US dollars and then showed a moderate increase again in 2024, reaching 784,100 thousand US dollars. Overall, the trend indicates heightened income tax provisions after 2021, with some volatility but maintaining higher levels than in the initial years.
- Cash operating taxes
- Cash operating taxes exhibited a strong upward trend from 2020 through 2023. Starting at 137,080 thousand US dollars in 2020, the cash taxes increased substantially to 556,675 thousand in 2021. This upward trajectory continued sharply into 2022, nearly doubling to 1,170,431 thousand US dollars. The peak was maintained in 2023 with 1,178,814 thousand US dollars, indicating stable but very high cash tax payments during that year. In 2024, cash operating taxes decreased to 1,029,919 thousand US dollars, showing a notable decline but remaining considerably elevated compared to 2020 and 2021.
- Comparative Insights
- Both provision for income taxes and cash operating taxes increased considerably after 2021, with cash operating taxes showing a more pronounced and consistent rise through 2023. The provision for income taxes experienced a sharp spike in 2022, followed by some reduction but remaining high through 2024. Cash operating taxes, while declining in 2024, stayed substantially higher than earlier years. This pattern could indicate changes in taxable income, tax planning strategies, or tax rate adjustments, resulting in elevated tax-related expenses and payments in recent years.
Invested Capital
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 Addition of capitalized operating leases.
2 Elimination of deferred taxes from assets and liabilities. See details »
3 Addition of equity equivalents to shareholders’ equity.
4 Removal of accumulated other comprehensive income.
5 Subtraction of marketable securities.
- Total Reported Debt & Leases
- The total reported debt and leases experienced a general decline from 2020 through 2023, decreasing from 942,460 thousand US dollars to 808,400 thousand US dollars. However, in 2024, there was a significant increase to 1,749,500 thousand US dollars, more than doubling the previous year's figure. This suggests a notable rise in leverage or financing activities in the most recent year.
- Shareholders’ Equity
- Shareholders' equity demonstrated a consistent upward trend from 2020 to 2023, increasing from 8,686,815 thousand US dollars to 17,580,400 thousand US dollars. This growth reflects an accumulation of retained earnings or capital injections over the years. In 2024, there was a slight decline to 16,409,600 thousand US dollars, indicating a minor reduction in equity, which may reflect distributions to shareholders, losses, or other equity adjustments.
- Invested Capital
- Invested capital rose steadily from 8,144,266 thousand US dollars in 2020 to 13,278,000 thousand US dollars in 2022. A plateau occurred between 2022 and 2023 with a marginal increase to 13,244,000 thousand US dollars. This was followed by a substantial decrease in 2024 to 9,046,000 thousand US dollars. This pattern may indicate a reduction in operating assets or a strategic realignment of capital deployment in the most recent period.
Cost of Capital
Vertex Pharmaceuticals Inc., cost of capital calculations
Capital (fair value)1 | Weights | Cost of capital | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity2 | ÷ | = | × | = | |||||||||
Finance lease liabilities3 | ÷ | = | × | × (1 – 21.00%) | = | ||||||||
Operating lease liability4 | ÷ | = | × | × (1 – 21.00%) | = | ||||||||
Total: |
Based on: 10-K (reporting date: 2024-12-31).
1 US$ in thousands
2 Equity. See details »
3 Finance lease liabilities. See details »
4 Operating lease liability. See details »
Capital (fair value)1 | Weights | Cost of capital | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity2 | ÷ | = | × | = | |||||||||
Finance lease liabilities3 | ÷ | = | × | × (1 – 21.00%) | = | ||||||||
Operating lease liability4 | ÷ | = | × | × (1 – 21.00%) | = | ||||||||
Total: |
Based on: 10-K (reporting date: 2023-12-31).
1 US$ in thousands
2 Equity. See details »
3 Finance lease liabilities. See details »
4 Operating lease liability. See details »
Capital (fair value)1 | Weights | Cost of capital | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity2 | ÷ | = | × | = | |||||||||
Finance lease liabilities3 | ÷ | = | × | × (1 – 21.00%) | = | ||||||||
Operating lease liability4 | ÷ | = | × | × (1 – 21.00%) | = | ||||||||
Total: |
Based on: 10-K (reporting date: 2022-12-31).
1 US$ in thousands
2 Equity. See details »
3 Finance lease liabilities. See details »
4 Operating lease liability. See details »
Capital (fair value)1 | Weights | Cost of capital | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity2 | ÷ | = | × | = | |||||||||
Finance lease liabilities3 | ÷ | = | × | × (1 – 21.00%) | = | ||||||||
Operating lease liability4 | ÷ | = | × | × (1 – 21.00%) | = | ||||||||
Total: |
Based on: 10-K (reporting date: 2021-12-31).
1 US$ in thousands
2 Equity. See details »
3 Finance lease liabilities. See details »
4 Operating lease liability. See details »
Capital (fair value)1 | Weights | Cost of capital | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity2 | ÷ | = | × | = | |||||||||
Finance lease liabilities3 | ÷ | = | × | × (1 – 21.00%) | = | ||||||||
Operating lease liability4 | ÷ | = | × | × (1 – 21.00%) | = | ||||||||
Total: |
Based on: 10-K (reporting date: 2020-12-31).
1 US$ in thousands
2 Equity. See details »
3 Finance lease liabilities. See details »
4 Operating lease liability. See details »
Economic Spread Ratio
Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
---|---|---|---|---|---|---|
Selected Financial Data (US$ in thousands) | ||||||
Economic profit1 | ||||||
Invested capital2 | ||||||
Performance Ratio | ||||||
Economic spread ratio3 | ||||||
Benchmarks | ||||||
Economic Spread Ratio, Competitors4 | ||||||
AbbVie Inc. | ||||||
Amgen Inc. | ||||||
Bristol-Myers Squibb Co. | ||||||
Danaher Corp. | ||||||
Eli Lilly & Co. | ||||||
Gilead Sciences Inc. | ||||||
Johnson & Johnson | ||||||
Merck & Co. Inc. | ||||||
Pfizer Inc. | ||||||
Regeneron Pharmaceuticals Inc. | ||||||
Thermo Fisher Scientific Inc. |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 Economic profit. See details »
2 Invested capital. See details »
3 2024 Calculation
Economic spread ratio = 100 × Economic profit ÷ Invested capital
= 100 × ÷ =
4 Click competitor name to see calculations.
- Economic Profit
- Over the observed periods, economic profit experienced significant fluctuations. Starting from a high point of approximately 2,313 million US dollars in 2020, it declined sharply to about 1,420 million in 2021. There was a moderate recovery in 2022 to roughly 1,834 million, followed by a decrease again in 2023 to around 1,479 million. Notably, in 2024, economic profit turned negative, reporting a loss of approximately 2,061 million US dollars. This indicates a substantial deterioration in value creation by the end of the period.
- Invested Capital
- Invested capital exhibited an overall upward trend until 2023, increasing from about 8,144 million US dollars in 2020 to a peak of approximately 13,244 million in 2023. However, in 2024, there was a notable contraction, with invested capital decreasing sharply to around 9,046 million US dollars. This suggests a reduction in the assets or capital base employed by the company in its operations during the final period.
- Economic Spread Ratio
- The economic spread ratio revealed a decreasing trend over the five years. It started at a strong 28.4% in 2020 but declined steadily each year to 15.13% in 2021, 13.92% in 2022, and 11.17% in 2023. In 2024, it sharply fell to a negative value of -22.78%, indicating that the returns on invested capital fell below the cost of capital and resulted in value destruction. This decline mirrors the negative economic profit observed in the same year.
- Overall Analysis
- The data suggest an initial period of strong economic performance followed by a gradual weakening of profitability metrics. The combination of rising invested capital with declining economic spread points to diminishing efficiency in capital utilization. The negative economic profit and economic spread ratio in the last reported year highlight a critical reversal, signaling possible operational or market challenges impacting value creation.
Economic Profit Margin
Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
---|---|---|---|---|---|---|
Selected Financial Data (US$ in thousands) | ||||||
Economic profit1 | ||||||
Revenues | ||||||
Performance Ratio | ||||||
Economic profit margin2 | ||||||
Benchmarks | ||||||
Economic Profit Margin, Competitors3 | ||||||
AbbVie Inc. | ||||||
Amgen Inc. | ||||||
Bristol-Myers Squibb Co. | ||||||
Danaher Corp. | ||||||
Eli Lilly & Co. | ||||||
Gilead Sciences Inc. | ||||||
Johnson & Johnson | ||||||
Merck & Co. Inc. | ||||||
Pfizer Inc. | ||||||
Regeneron Pharmaceuticals Inc. | ||||||
Thermo Fisher Scientific Inc. |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 Economic profit. See details »
2 2024 Calculation
Economic profit margin = 100 × Economic profit ÷ Revenues
= 100 × ÷ =
3 Click competitor name to see calculations.
The analysis of the financial data over the five-year period shows significant fluctuations in both economic profit and economic profit margin, despite a steady increase in revenues.
- Revenues
- Revenues have exhibited consistent growth from US$6.21 billion in 2020 to US$11.02 billion in 2024. This represents an overall increase of approximately 77.6% over the period, indicating strong top-line growth year over year.
- Economic Profit
- Economic profit starts at a high of approximately US$2.31 billion in 2020 but declines sharply to about US$1.42 billion in 2021. It recovers somewhat in 2022 to US$1.83 billion and then decreases again to US$1.48 billion in 2023. A significant downturn occurs in 2024, with economic profit turning negative to approximately -US$2.06 billion. This suggests a deterioration in value generation and possibly higher costs or lower margins offsetting revenue growth.
- Economic Profit Margin
- The economic profit margin mirrors the trend in economic profit. It starts strong at 37.27% in 2020 and drops to 18.75% in 2021, showing a substantial decline in profitability relative to revenues. It modestly improves to 20.54% in 2022 but declines again to 14.99% in 2023. In 2024, the margin turns negative to -18.7%, indicating that economic profit is negative relative to revenues, highlighting a significant loss in profitability and potential inefficiencies or increased expenses.
In summary, although revenues have steadily increased over the examined period, both economic profit and its margin have fluctuated drastically, culminating in a negative economic profit and margin in the latest year. This indicates that while sales growth continues, profitability and economic value creation have weakened markedly, especially in the last year.